Physician profile
Troy T Pulas
NPI 1407074263
$5,790.81
in general payments reported to CMS, 2019-2025
23 companies · $2,506 in 2025
The $2,506 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $197 · 2021: $59.51 · 2022: $27.95 · 2023: $1,438 · 2024: $1,383 · 2025: $2,506.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,127 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,127.00 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $922.72 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $849.17 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $602.68 | 2024-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $587.83 | 2020-2025 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $478.64 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $446.11 | 2023-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $363.19 | 2023-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $244.28 | 2023-2025 | Qelbree, Qelbree |
| Janssen Scientific Affairs, LLC | $200.00 | 2025 | Spravato |
| E.R. Squibb & Sons, L.L.C. | $172.78 | 2024-2025 | Cobenfy |
| Almatica Pharma LLC | $139.78 | 2023-2025 | Loreev Xr |
| Abbvie INC. | $118.90 | 2021-2024 | |
| Lundbeck LLC | $103.51 | 2023-2025 | Rexulti |
| Axsome Therapeutics, INC. | $101.54 | 2024-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $73.07 | 2023-2025 | Quviviq, Quviviq |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $70.84 | 2025 | Brixadi |
| Corium, LLC | $69.41 | 2023 | Azstarys |
| Allergan, INC. | $68.46 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $60.70 | 2022-2023 | Trintellix |
| Sage Therapeutics, LLC | $53.33 | 2024 | |
| Indivior INC. | $37.63 | 2024-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $13.21 | 2020 | |
| Neos Therapeutics, LP | $13.03 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Troy Pulas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.